American Journal of Kidney Diseases最新文献

{"title":"Identifying Major Barriers to Home Dialysis (The IM-HOME Study): Findings From a National Survey of Patients, Care Partners, and Providers","authors":"","doi":"10.1053/j.ajkd.2024.04.007","DOIUrl":"10.1053/j.ajkd.2024.04.007","url":null,"abstract":"<div><h3>Rationale & Objective</h3><div>Developing strategies to improve home dialysis use requires a comprehensive understanding of barriers. We sought to identify the most important barriers to home dialysis use from the perspective of patients, care partners, and providers.</div></div><div><h3>Study Design</h3><div>This is a convergent parallel mixed-methods study.</div></div><div><h3>Setting & Participants</h3><div>We convened a 7-member advisory board of patients, care partners, and providers who collectively developed lists of major patient/care partner-perceived barriers and provider-perceived barriers to home dialysis. We used these lists to develop a survey that was distributed to patients, care partners, and providers—through the American Association of Kidney Patients and the National Kidney Foundation. The surveys asked participants to (1) rank their top 3 major barriers (quantitative) and (2) describe barriers to home dialysis (qualitative).</div></div><div><h3>Analytical Approach</h3><div>We compiled a list of the top 3 patient/care partner-perceived and top 3 provider-perceived barriers (quantitative). We also conducted a directed content analysis of open-ended survey responses (qualitative).</div></div><div><h3>Results</h3><div>There were 522 complete responses (233 providers; 289 patients/care partners). The top 3 patient/care partner-perceived barriers were fear of performing home dialysis; lack of space; and the need for home-based support. The top 3 provider-perceived barriers were poor patient education; limited mechanisms for home-based support staff, mental health, and education; and lack of experienced staff. We identified 9 themes through qualitative analysis: limited education; financial disincentives; limited resources; high burden of care; built environment/structure of care delivery that favors in-center hemodialysis; fear and isolation; perceptions of inequities in access to home dialysis; provider perspectives about patients; and patient/provider resiliency.</div></div><div><h3>Limitations</h3><div>This was an online survey that is subject to nonresponse bias.</div></div><div><h3>Conclusions</h3><div>The top 3 barriers to home dialysis for patient/care partners and providers incompletely overlap, suggesting the need for diverse strategies that simultaneously address patient-perceived barriers at home and provider-perceived barriers in the clinic.</div></div><div><h3>Plain-Language Summary</h3><div>There are many barriers to home dialysis use in the United States. However, we know little about which barriers are the most important to patients and clinicians. This makes it challenging to develop strategies to increase home dialysis use. In this study, we surveyed patients, care partners, and clinicians across the country to identify the most important barriers to home dialysis, namely (1) patients/care partners identified fear of home dialysis, lack of space, and lack of home-based support; and (2) clinicians ","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":null,"pages":null},"PeriodicalIF":9.4,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141293007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Going From Point A to Point B: Changes in the Mobility of Older Persons With CKD","authors":"","doi":"10.1053/j.ajkd.2024.03.015","DOIUrl":"10.1053/j.ajkd.2024.03.015","url":null,"abstract":"","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":null,"pages":null},"PeriodicalIF":9.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0272638624007418/pdfft?md5=9255d521334a61bf4964e7cfec5fd9f8&pid=1-s2.0-S0272638624007418-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141199250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Use of Ultrasound in Peritoneal Dialysis Setting.","authors":"Andreia Curto, Tiago Assis Pereira, Ana Carina Ferreira","doi":"10.1053/j.ajkd.2024.03.027","DOIUrl":"10.1053/j.ajkd.2024.03.027","url":null,"abstract":"","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":null,"pages":null},"PeriodicalIF":9.4,"publicationDate":"2024-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141183350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In Reply to \"The Use of Ultrasound in Peritoneal Dialysis Setting\".","authors":"Vandana Dua Niyyar","doi":"10.1053/j.ajkd.2024.04.006","DOIUrl":"10.1053/j.ajkd.2024.04.006","url":null,"abstract":"","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":null,"pages":null},"PeriodicalIF":9.4,"publicationDate":"2024-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141183347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations of Urine and Plasma Metabolites With Kidney Failure and Death in a Chronic Kidney Disease Cohort","authors":"","doi":"10.1053/j.ajkd.2024.03.028","DOIUrl":"10.1053/j.ajkd.2024.03.028","url":null,"abstract":"<div><h3>Rationale & Objective</h3><div>Biomarkers that enable better identification of persons with chronic kidney disease (CKD) who are at higher risk for disease progression and adverse events are needed. This study sought to identify urine and plasma metabolites associated with progression of kidney disease.</div></div><div><h3>Study Design</h3><div>Prospective metabolome-wide association study.</div></div><div><h3>Setting & Participants</h3><div>Persons with CKD enrolled in the GCKD (German CKD) study with metabolite measurements, with external validation within the ARIC (Atherosclerosis Risk in Communities) Study.</div></div><div><h3>Exposures</h3><div>1,513 urine and 1,416 plasma metabolites (Metabolon Inc) measured at study entry using untargeted mass spectrometry.</div></div><div><h3>Outcomes</h3><div>Main end points were kidney failure (KF) and a composite kidney end point (CKE) of KF, estimated glomerular filtration rate<!--> <!--><15<!--> <!-->mL/min/1.73<!--> <!-->m<sup>2</sup>, or a 40% decrease in estimated glomerular filtration rate. Death from any cause was a secondary end point. After a median of 6.5 years of follow-up, 500 persons had experienced KF, 1,083 had experienced the CKE, and 680 had died.</div></div><div><h3>Analytical Approach</h3><div>Time-to-event analyses using multivariable proportional hazard regression models in a discovery–replication design with external validation.</div></div><div><h3>Results</h3><div>5,088 GCKD study participants were included in analyses of urine metabolites, and 5,144 were included in analyses of plasma metabolites. Among 182 unique metabolites, 30 were significantly associated with KF, 49 with the CKE, and 163 with death. The strongest association with KF was observed for plasma hydroxyasparagine (HR, 1.95; 95% CI, 1.68-2.25). An unnamed metabolite measured in plasma and urine was significantly associated with KF, the CKE, and death. External validation of the identified associations of metabolites with KF or the CKE revealed directional consistency for 88% of observed associations. Selected associations of 18 metabolites with study outcomes have not been previously reported.</div></div><div><h3>Limitations</h3><div>Use of observational data and semiquantitative metabolite measurements at a single time point.</div></div><div><h3>Conclusions</h3><div>The observed associations between metabolites and KF, the CKE, or death in persons with CKD confirmed previously reported findings and also revealed several associations not previously described. These findings warrant confirmatory research in other study cohorts.</div></div><div><h3>Plain-Language Summary</h3><div>Incomplete understanding of the variability of chronic kidney disease (CKD) progression motivated the search for new biomarkers that would help identify people at increased risk. We explored metabolites in plasma and urine for their association with unfavorable kidney outcomes or death in persons with CKD. Metabolomic an","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":null,"pages":null},"PeriodicalIF":9.4,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141178657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving Diverse and Equitable Involvement of Patients and Caregivers in Research in CKD: Report of a Better Evidence and Translation–Chronic Kidney Disease (BEAT-CKD) Workshop","authors":"","doi":"10.1053/j.ajkd.2024.03.026","DOIUrl":"10.1053/j.ajkd.2024.03.026","url":null,"abstract":"<div><div>Patient and caregiver involvement can enhance the uptake and impact of research, but the involvement of patients and caregivers who are underserved and marginalized is often limited. A better understanding of how to make involvement in research more broadly accessible, supportive, and inclusive for patients with chronic kidney disease (CKD) and caregivers is needed. We conducted a national workshop involving patients, caregivers, clinicians, and researchers from across Australia to identify strategies to increase the diversity of patients and caregivers involved in CKD research. Six themes were identified. <em>Building trust and a sense of safety</em> was considered pivotal to establishing meaningful relationships to support knowledge exchange. <em>Establishing community and connectedness</em> was expected to generate a sense of belonging to motivate involvement. <em>Balancing stakeholder goals, expectations, and responsibilities</em> involved demonstrating commitment and transparency by researchers. <em>Providing adequate resources and support</em> included strategies to minimize the burden of involvement for patients and caregivers. <em>Making research accessible and relatable</em> was about nurturing patient and caregiver interest by appealing to intrinsic motivators. <em>Adapting to patient and caregiver needs and preferences</em> required tailoring the approach for individuals and the target community. Strategies and actions to support these themes may support more diverse and equitable involvement of patients and caregivers in research in CKD.</div></div>","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":null,"pages":null},"PeriodicalIF":9.4,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141174155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vitamin D Metabolites Before and After Kidney Transplantation in Patients Who Are Anephric","authors":"","doi":"10.1053/j.ajkd.2024.03.025","DOIUrl":"10.1053/j.ajkd.2024.03.025","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Rationale &amp; Objective&lt;/h3&gt;&lt;div&gt;Kidneys are vital for vitamin D&lt;span&gt;&lt;span&gt; metabolism, and disruptions in both production and catabolism occur in chronic kidney disease. Although &lt;/span&gt;vitamin D&lt;span&gt;&lt;span&gt; activation occurs in numerous tissues, the kidneys are the most relevant source of circulating active vitamin D. This study investigates extrarenal vitamin D activation and the impact of kidney transplantation on &lt;/span&gt;vitamin D metabolism in patients who are anephric.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Study Design&lt;/h3&gt;&lt;div&gt;Case series.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Setting &amp; Participants&lt;/h3&gt;&lt;div&gt;&lt;span&gt;Adult patients with previous bilateral nephrectomy (anephric) not receiving active vitamin D therapy evaluated at the time of (N&lt;/span&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;38) and 1 year after (n&lt;!--&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;25) kidney transplantation.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Analytical Approach&lt;/h3&gt;&lt;div&gt;&lt;span&gt;&lt;span&gt;Chromatography with tandem mass spectrometry was used to measure vitamin D metabolites. Activity of &lt;/span&gt;CYP24A1 [24,25(OH)&lt;/span&gt;&lt;sub&gt;2&lt;/sub&gt;D/25(OH)D] and CYP27B1 [1α,25(OH)&lt;sub&gt;2&lt;/sub&gt;D/25(OH)D] is expressed as metabolic ratios. Differences between time points were evaluated by paired &lt;em&gt;t&lt;/em&gt;-test or Wilcoxon matched-pairs signed-rank test.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;At time of transplantation, 1α,25(OH)&lt;sub&gt;2&lt;/sub&gt;D was detectable in all patients (4-36&lt;!--&gt; &lt;!--&gt;pg/mL). There was a linear relationship between 25(OH)D and 1α,25(OH)&lt;sub&gt;2&lt;/sub&gt;D levels (r&lt;!--&gt; &lt;em&gt;=&lt;/em&gt; &lt;!--&gt;0.58, P&lt;!--&gt; &lt;!--&gt;&lt;&lt;!--&gt; &lt;!--&gt;0.001), with 25(OH)D explaining 34% of the variation in 1α,25(OH)&lt;sub&gt;2&lt;/sub&gt;D levels. There were no associations between 1α,25(OH)&lt;sub&gt;2&lt;/sub&gt;&lt;span&gt;&lt;span&gt;D and biointact parathyroid hormone (PTH) or &lt;/span&gt;fibroblast growth factor 23 (FGF-23). One year after transplantation, 1α,25(OH)&lt;/span&gt;&lt;sub&gt;2&lt;/sub&gt;D levels recovered (+205%), and CYP27B1 activity increased (+352%). Measures of vitamin D catabolism, 24,25(OH)&lt;sub&gt;2&lt;/sub&gt;&lt;span&gt;D and CYP24A1 activity increased 3- to 5-fold. Also, at 12 months after transplantation, 1α,25(OH)&lt;/span&gt;&lt;sub&gt;2&lt;/sub&gt;D was positively correlated with PTH (ρ&lt;!--&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;0.603, &lt;em&gt;P&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;0.04) but not with levels of 25(OH)D or FGF-23.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Limitations&lt;/h3&gt;&lt;div&gt;Retrospective, observational study design with a small cohort size.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;Low-normal levels of 1α,25(OH)&lt;sub&gt;2&lt;/sub&gt;D was demonstrated in anephric patients, indicating production outside the kidneys. This extrarenal CYP27B1 activity may be more substrate driven than hormonally regulated. Kidney transplantation seems to restore kidney CYP27B1 and CYP24A1 activity, as evaluated by vitamin D metabolic ratios, resulting in both increased vitamin D production and catabolism. These findings may have implications for vitamin D supplementation strategies in the setting of kidney failure and transplantation.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Plain-Language Summary&lt;/h3&gt;&lt;div&gt;Vitamin D activation occu","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":null,"pages":null},"PeriodicalIF":9.4,"publicationDate":"2024-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141131377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Organization and Structures for Detection and Monitoring of CKD Across World Countries and Regions: Observational Data From a Global Survey","authors":"","doi":"10.1053/j.ajkd.2024.03.024","DOIUrl":"10.1053/j.ajkd.2024.03.024","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Rationale &amp; Objective&lt;/h3&gt;&lt;div&gt;Established therapeutic interventions effectively mitigate the risk and progression of chronic kidney disease (CKD). Countries and regions have a compelling need for organizational structures that enable early identification of people with CKD who can benefit from these proven interventions. We report the current global status of CKD detection programs.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Study Design&lt;/h3&gt;&lt;div&gt;A multinational cross-sectional survey.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Setting &amp; Participants&lt;/h3&gt;&lt;div&gt;Stakeholders, including nephrologist leaders, policymakers, and patient advocates from 167 countries, participating in the International Society of Nephrology (ISN) survey from June to September 2022.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Outcome&lt;/h3&gt;&lt;div&gt;Structures for the detection and monitoring of CKD, including CKD surveillance systems in the form of registries, community-based detection programs, case-finding practices, and availability of measurement tools for risk identification.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Analytical Approach&lt;/h3&gt;&lt;div&gt;Descriptive statistics.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Of all participating countries, 19% (n&lt;!--&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;31) reported CKD registries, and 25% (n&lt;!--&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;40) reported implementing CKD detection programs as part of their national policies. There were variations in CKD detection program, with 50% (n&lt;!--&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;20) using a reactive approach (managing cases as identified) and 50% (n&lt;!--&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;20) actively pursuing case-finding in at-risk populations. Routine case-finding for CKD in high-risk populations was widespread, particularly for diabetes (n&lt;!--&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;152; 91%) and hypertension (n&lt;!--&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;148; 89%). Access to diagnostic tools, estimated glomerular filtration rate (eGFR), and urine albumin-creatinine ratio (UACR) was limited, especially in low-income (LICs) and lower-middle-income (LMICs) countries, at primary (eGFR: LICs 22%, LMICs 39%, UACR: LICs 28%, LMICs 39%) and secondary/tertiary health care levels (eGFR: LICs 39%, LMICs 73%, UACR: LICs 44%, LMICs 70%), potentially hindering CKD detection.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Limitations&lt;/h3&gt;&lt;div&gt;A lack of detailed data prevented an in-depth analysis.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;This comprehensive survey highlights a global heterogeneity in the organization and structures (surveillance systems and detection programs and tools) for early identification of CKD. Ongoing efforts should be geared toward bridging such disparities to optimally prevent the onset and progression of CKD and its complications.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Plain-Language Summary&lt;/h3&gt;&lt;div&gt;Early detection and management of chronic kidney disease (CKD) is crucial to prevent progression to kidney failure. A multinational survey across 167 countries revealed disparities in CKD detection programs. Only 19% reported CKD registries, and 25% implemented detection programs as part of their national policy. Half used a re","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":null,"pages":null},"PeriodicalIF":9.4,"publicationDate":"2024-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141092272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum regarding “Non-GFR Determinants of Low-Molecular-Weight Serum Protein Filtration Markers in CKD” (Am J Kidney Dis. 2016;68(6):892-900)","authors":"","doi":"10.1053/j.ajkd.2024.04.001","DOIUrl":"10.1053/j.ajkd.2024.04.001","url":null,"abstract":"","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":null,"pages":null},"PeriodicalIF":13.2,"publicationDate":"2024-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0272638624006875/pdfft?md5=db7c1103bdd115f4297f1480cceb15cf&pid=1-s2.0-S0272638624006875-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141086499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum regarding “A New Panel-Estimated GFR, Including β2-Microglobulin and β-Trace Protein and Not Including Race, Developed in a Diverse Population” (Am J Kidney Dis. 2021;77(5):673-683)","authors":"","doi":"10.1053/j.ajkd.2024.04.003","DOIUrl":"10.1053/j.ajkd.2024.04.003","url":null,"abstract":"","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":null,"pages":null},"PeriodicalIF":13.2,"publicationDate":"2024-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0272638624006899/pdfft?md5=9f11ddaacb8455323a83e6b08ceb73e9&pid=1-s2.0-S0272638624006899-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141086497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}